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Dermatitis induced by Toll-like receptor 7 agonist acceler-
ates dextran sulfate sodium colitis accompanied with
decreased naive B cells and a perturbed microbiome with
reduced Lactobacillus species in the gut. We show the skin–
gut axis is associated with the gut microbiome.
BACKGROUND & AIMS: Psoriasis and inﬂammatory bowel
disease (IBD) are both chronic inﬂammatory diseases occurring
in the skin and gut, respectively. It is well established that
psoriasis and IBD have high concordance rates, and similar
changes in immune cells and microbiome composition have been
reported in both conditions. To study this connection, we used a
combination murine model of psoriatic dermatitis and colitis in
which mice were treated topically with the Toll-like receptor 7
agonist imiquimod (IMQ) and fed dextran sulfate sodium (DSS).
METHODS: We applied IMQ topically to B6 mice (IMQ mice)
and subsequently fed them 2% DSS in their drinking water.
Disease activity and immune cell phenotypes were analyzed,and the microbial composition of fecal samples was investi-
gated using 16S ribosomal RNA sequencing. We transplanted
feces from IMQ mice to germ-free IQI/Jic (IQI) mice and fed
them DSS to assess the effect of the gut microbiome on disease.
RESULTS: We ﬁrst conﬁrmed that IMQ mice showed acceler-
ated DSS colitis. IMQ mice had decreased numbers of IgDþ and
IgMþ B cells and increased numbers of non–cytokine-producing
macrophages in the gut. Moreover, the gut microbiomes of IMQ
mice were perturbed, with signiﬁcant reductions of Lactoba-
cillus johnsonii and Lactobacillus reuteri populations. Germ-free
mice transplanted with feces from IMQ mice, but not with feces
from untreated mice, also developed exacerbated DSS colitis.
CONCLUSIONS: These results suggest that skin inﬂammation
may contribute to pathogenic conditions in the gut via immu-
nologic and microbiological changes. Our ﬁnding of a novel po-
tential skin–gut interaction provides new insights into the
coincidence of psoriasis and IBD. (Cell Mol Gastroenterol Hepatol
2019;7:135–156; https://doi.org/10.1016/j.jcmgh.2018.09.010)
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bacteria and the host immune system play signiﬁcant roles
in both homeostatic and disease processes. Perturbations
in the gut microbiome can contribute both to intestinal
disorders, such as inﬂammatory bowel disease (IBD), as
well as systemic diseases, including obesity, type 2 diabetes,
atherosclerosis, and multiple sclerosis. Gut microbes affect
the host immune system and vice versa: for instance, some
Clostridium species can induce regulatory T cell (Treg) dif-
ferentiation, and segmented ﬁlamentous bacteria can induce
T helper (Th)17 cell differentiation. Moreover, it has been
shown that interleukin (IL)10 knockout mice are colonized
by colitogenic microbes and develop spontaneous colitis.
Psoriasis is a chronic dermatitis with a prevalence of
2%–4% in Western countries and 0.9%–8.5% worldwide.1
Psoriasis and IBD share similar immunologic features,2–4
and polymorphisms in the Il12b and Il23r genes confer
increased susceptibility to both conditions.5,6 Therefore, a
mechanistic relationship between these conditions has been
suspected, and, indeed, these 2 diseases are known to
overlap. The prevalence of IBD in psoriatic patients is 4
times higher than in the general population,7,8 and the
prevalence of psoriasis in patients with Crohn’s disease is
higher than in healthy subjects.9 In addition to shared
immunologic features, patients with IBD and psoriasis have
similar gut microbial compositions.10,11 Recently, it was
reported that enteric viruses can activate plasmacytoid
dendritic cells (pDCs) via Toll-like receptor (TLR)7 signaling
to produce type I interferon (IFN), which then can amelio-
rate colitis.12 Administration of TLR7 agonists induced IL22
production by group 3 innate lymphoid cells (ILC3s), and
conferred increased resistance against colonization by
vancomycin-resistant enterococcus.13 Thus, TLR7 signaling
in the intestine may be beneﬁcial for gut homeostasis. These
ﬁndings seemingly contradict the evidence that patient
populations with psoriasis and IBD overlap. Topical appli-
cation of a TLR7 agonist (imiquimod [IMQ]) induces
dermatitis, a phenomenon that has been widely exploited as
a murine psoriasis model.14–16
We applied IMQ topically and administered dextran
sulfate sodium (DSS) enterally as murine models of
psoriasis-like dermatitis and colitis murine models, respec-
tively, and analyzed skin–gut interactions between immune
cells and gut microbes. We showed that IMQ-induced psori-
atic dermatitis accelerated the severity of DSS colitis. More-
over, IMQ dermatitis was associated with reduced numbers
of IgDþ and IgMþ B cells in the gut and altered composition
of the gut microbiome, with a marked reduction observed in
Lactobacillus species. Fecal transfer from IMQ-treated mice,
but not untreated mice, to germ-free (GF) mice resulted in
exacerbation of DSS colitis after transfer. Identifying potential
skin–gut interactions between the immune system and the
gut microbiome in murine models may help us understand
the coincidence of psoriasis and IBD and lead to improved
treatments for patients with these conditions.
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.Results
Murine Psoriasis-Like Dermatitis Induced Severe
DSS Colitis
First, we investigated whether psoriasis-like dermatitis
could induce spontaneous colitis in a murine model. We
topically applied IMQ to the shaved backs of mice for 6
consecutive days, followed by 3 days of rest. This treatment
was repeated for 2 cycles (IMQ mice). Vehicle alone was
topically applied instead of IMQ to the control mice
(Figure 1A). IMQ mice developed psoriasis-like dermatitis
(Figure 1B and C) but the animals did not develop sponta-
neous colitis (Figure 1D). To investigate potential in-
teractions between skin inﬂammation and colitis, we next
subjected the IMQ mice to a chemical colitis model. IMQ
mice were fed 2% (wt/vol) DSS in their drinking water for
7 days (IMQ-DSS mice) (Figure 1E). Compared with control
(cont)-DSS mice, IMQ-DSS mice showed more severe clinical
symptoms of colitis including body weight loss, shorter
colon length, loose stool consistency, and gross bleeding.
This phenotype was reﬂected in the increased disease
activity indexes (DAIs) of these animals (Figure 1F–I).
Histologic analyses of IMQ-DSS mice showed complete
destruction of the epithelial layer, loss of crypts, submucosal
edema, and intestinal inﬂammation with immune cell
inﬁltrates; histologic scores were signiﬁcantly higher in
IMQ-DSS mice than in cont-DSS mice (Figure 1J and K).
Taken together, these data showed that IMQ-DSS mice
developed more severe colitis than cont-DSS mice.
To assess the immune cell composition of the colonic
mucosa, we analyzed the frequencies of macrophages, B cells,
and T cells in IMQ-DSS and cont-DSS mice by ﬂow cytometry.
Although macrophage frequency was comparable between
the 2 groups, the proportion of CD80-expressing macro-
phages (M1-type macrophages) was slightly increased in
IMQ-DSS mice (Figure 1L–O). The frequency of B cells in the
colon was decreased signiﬁcantly in IMQ-DSS mice, whereas
the frequency of T cells in the colon was comparable between
the 2 groups (Figure 1P–R). We found no differences in the
frequencies of Th17 cells, Th1 cells, or Tregs between IMQ
and control mice (data not shown). Interestingly, the
numbers of IgDþ and IgMþ B cells were greatly decreased in
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numbers of IgAþ B cells and IgAþ plasma cells were not
signiﬁcantly different between the 2 groups (Figure 1S and
T). Co-staining with antibodies against fecal bacteria and IgA
showed that the proportion of fecal bacteria coated with
secretory IgA was comparable in IMQ-DSS and cont-DSS mice
(Figure 1U). These data indicate that IMQ dermatitis induced
severe DSS colitis as well as decreased numbers of naive B
cells and increased numbers of M1 macrophages in the gut.IMQ Dermatitis Mice Did Not Increase Intestinal
Permeability but Altered Immune Cell
Composition in the Intestine
We next determined whether intestinal permeability and
immunologic changes occurred in these animals before DSS
challenge. To assess intestinal permeability, we adminis-
tered 4 or 70 kilodaltons of ﬂuorescein isothiocyanate
(FITC)-dextran to fasting mice by oral gavage and analyzed
plasma concentrations of FITC-dextran. Plasma levels of
FITC-dextran were comparable in IMQ and control mice
(Figure 2A). We also conﬁrmed that expression of tran-
scripts encoding the tight junction–associated proteins,
zonula occludens-1 (ZO-1) and occludin, were not decreased
in IMQ mice (Figure 2B). Western blot analysis of epithelial
cells in IMQ mice showed occludin protein was not
decreased (Figure 2C). Immunoﬂuorescence staining of
ZO-1, occludin, and claudin-2 were not decreased in colons
of IMQ mice (Figure 2D and E). These data suggest that
intestinal permeability was not increased in IMQ mice. We
also conﬁrmed that the expression of transcripts encoding
the antimicrobial peptide Reg IIIg was not decreased in IMQ
mice (Figure 2F). We observed that macrophage frequency
in the gut was increased in IMQ mice (Figure 2G). Although
the proportions of M1 (CD80þ) and M2 (CD206þ) macro-
phages were decreased in IMQ mice compared with control
mice (Figure 2H), the absolute numbers of these cells were
comparable. We next compared messenger RNA expression
of CD11bþ cells derived from colonic lamina propria (LP)
(CD11bþ cells) of IMQ and control mice. The relative
expression of transcripts encoding proinﬂammatory cyto-
kines such as tumor necrosis factor (TNF)-a, IL6, and IL12BFigure 1. (See previous page). Psoriasis-like dermatitis exace
psoriasis-like dermatitis by IMQ. (B) Skin appearance of psoria
Clinical score for psoriasis-like dermatitis (psoriasis area severit
(D) Representative H&E staining of colon sections at the end of I
protocol. Mice treated topically with IMQ or vehicle as shown in
(wt/vol) DSS for 7 days (n ¼ 8 in each group). (F) Body weigh
photograph of colon on day 7 of DSS colitis. (H) Colon length on
Representative H&E staining of distal colon section on day 7 of
on day 7 of DSS colitis. (L) Representative plots of ﬂow cytome
lineage-CD11bþCD64þ cells). The plots are gated on CD45þCD
number (right) of colonic lamina propria macrophages. (N and O
macrophages in colonic lamina propria. Percentage of CD80þ ce
analysis for CD45þ colonic lamina propria lymphocytes. (Q and R
(right) in CD45þ cells. (S) Absolute number of IgAþ B cells (lef
sentative plots of ﬂow cytometry analysis for IgAþ plasma cells i
plots are gated on CD45þCD3-CD4-CD8-NK1.1- cells. (U) Percen
Each symbol represents an individual mouse (n ¼ 3–8). Statistic
**P < .01, ***P < .001, NS; not signiﬁcant. Error bars representwas reduced signiﬁcantly in IMQ mice. Expression of IL10,
an anti-inﬂammatory cytokine, was also slightly decreased,
but this was not statistically signiﬁcantly (P ¼ .063)
(Figure 2I). Expression of Nos2 and Arg1 were not different
between the 2 groups. We collected LP CD11bþ cells from
IMQ and control mice and cultured them in vitro in the
presence of lipopolysaccharide or peptidoglycan. Production
of macrophage chemoattractant protein-1 by LP CD11bþ
cells was comparable between IMQ and control mice,
whereas production of IL10, TNF-a, and IL6 was decreased
signiﬁcantly in LP CD11bþ cells derived from IMQ mice
(Figure 2J). Collectively, these data suggest that IMQ
dermatitis increased the frequency of intestinal macrophages,
but that these macrophages were impaired in their ability to
produce both proinﬂammatory and anti-inﬂammatory cyto-
kines (TNF-a, IL6, and IL10) against pathogen-associated
molecular patterns. Because previous studies have shown
that IMQ could activate the NACHT, LRR, and PYD domains-
containing protein 3 (NLRP3) inﬂammasome in macro-
phages,17 we analyzed NLRP3 expression in peritoneal cavity
cells. However, NLRP3 expression in peritoneal cells was
unaltered in IMQ mice (Figure 2K). IMQ is known to affect
pDC and ILC3 populations,13 but the proportions of pDCs and
ILC3s were unaltered in IMQ mice compared with control
animals (Figure 2L and M).
We next investigated the proportions of Th1 and Th17
cells and Tregs in colonic lamina propria, but did not ﬁnd any
differences between IMQ and control mice (Figure 3A, B, and
D–G). Meanwhile, the number of colonic B cells was
decreased drastically in IMQ mice (Figure 3A and C), mainly
owing to reductions in IgDþ and IgMþ B cells not in IgAþ B
cells (Figure 3H). The percentage of plasma cells was not
decreased before DSS administration to IMQ mice (Figure 3I).
Because the amount of fecal IgA is known to affect dysbiosis,
we also analyzed the concentration of secretory IgA and
the proportion of IgA-coated bacteria in feces. Fecal IgA
and IgA-coated bacteria levels were unaltered in IMQ mice, as
we expected (Figure 3J and K). Taken together, IMQ mice did
not increase intestinal permeability. IMQ mice reduced the
number of IgDþ and IgMþ B cells and increased the number
of macrophages that were impaired in their ability to pro-
duce cytokines in the gut before DSS administration.rbates DSS colitis. (A) Experimental protocol for induction of
sis-like dermatitis on day 14 of IMQ or vehicle treatment. (C)
y index [PASI] score) at the end of IMQ treatment (on day 17).
MQ treatment (on day 17). Scale bar: 100 mm. (E) Experimental
panel A, were subsequently induced with acute colitis by 2%
t changes during administration of DSS. (G) Representative
day 7 of DSS colitis. (I) DAI score on day 7 of DSS colitis. (J)
DSS colitis. Scale bar: 100 mm. (K) Histologic score for colitis
try analysis for colonic lamina propria macrophages (CD45þ
3-CD19-B220-NK1.1- cells. (M) Percentage (left) and absolute
) Representative plots of ﬂow cytometry analysis for CD80þ
lls in macrophages. (P) Representative plots of ﬂow cytometry
) Percentage and absolute number of B cells (left) and T cells
t), IgDþ B cells (middle), and IgMþ B cells (right). (T) Repre-
n colonic lamina propria (left) and absolute number (right). The
tage of IgA-coated fecal bacteria analyzed by ﬂow cytometry.
al analyses were performed with the Student t test. *P < .05,
the SEM of samples within a group.
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Not Caused by Migration to Skin or
Skin-Draining Lymph Nodes, or by
Systemic B-Cell Depletion
We then hypothesized that IMQ dermatitis might cause
gut-naive B cells to migrate to skin lesions or skin draining
lymph nodes (dLNs). We analyzed the immune cell
composition of both the dermis and epidermis of lesions as
well as skin dLNs after IMQ application. The ratio of B cells
was comparable in the dermis and epidermis of IMQ and
control mice (Figure 3L–N). Similarly, the frequency of B
cells was unaltered in skin dLNs of IMQ mice
(Figure 3L–N). By contrast, as we previously found in the
colon, the total numbers of B cells, IgDþ B cells, and IgMþ
B cells were decreased in mesenteric lymph nodes of IMQ
mice compared with control mice. To exclude the possi-
bility of systemic B-cell reduction in IMQ mice, we
analyzed splenic B cells and conﬁrmed that splenic B cells
were not decreased by IMQ application (Figure 3L and M).
We also analyzed Th17 cells, Th1 cells, and Tregs in each
organ. Both Tregs and Th17 cells were increased in skin
dLNs and mesenteric lymph nodes. Th1 cells were slightly
increased in skin dLNs. However, the ratio of Th17, Th1,
and Tregs did not increase in the colons of IMQ mice
(Figure 3D–G). These data indicate that colonic IgDþ and
IgMþ B cells in IMQ mice did not migrate to skin or
skin dLNs.Psoriasis-Like Dermatitis Was Required to Induce
Immunologic Changes in the Gut and to
Exacerbate DSS Colitis
We next assessed whether psoriasis-like dermatitis was
required for immunologic changes and severe colitis to
occur in the gut after IMQ treatment. First, we applied IMQ
to TLR7-/- mice (IMQ-DTLR7) to determine whetherFigure 2. (See previous page). IMQ dermatitis mice did not
composition in the intestine. (A) Analysis for intestinal permea
IMQ or vehicle treatment), by using 4 kilodaltons (left) or 70 ki
trations were determined by ﬂuorescence intensity, after 1, 2 an
each group). Seventy kilodaltons FITC-dextran was administer
analysis for ZO-1 and occludin in colonic epithelial cells after top
Western blot analysis for occludin expression in colonic epithel
(left) and relative protein levels (right) of occludin. (D) Immunoﬂu
ZO-1 (top, green), occludin (middle, red), claudin (bottom, gree
colon tissue. Four to 5 sections from each mice were obtained
with the DAPI-positive area measured (n ¼ 4–5, each dot repres
colonic epithelial cells after topical IMQ treatment (on day 17)
cytometry analysis for macrophages (CD11bþCD64þ cells) in CD
treatment (on day 17) (n ¼ 6 in each group). Percentage (left) a
propria. (H and I) Percentage and absolute number of CD206
analysis of IL10, Tnf-a, Il6, IL12b, Arg-1, and Nos2 in LP CD11b
magnetic activated cell sorting from colonic lamina propria mon
CD11bþs were cultured with lipopolysaccharide (LPS) or pept
cytokines in the supernatant were measured by cytometric bead
(K) Western blot analysis for NLRP3 in peritoneal cavity cells, wh
and relative protein levels (right) of NLRP3 (n ¼ 7–8, pooled from
ILC3 in CD45þCD3-CD19- cells and (M) pDCs in CD45
CD45þCD3-CD19-Rorgtþ cells; pDC, CD45þCD11b-CD11cþB
mouse (n ¼ 4–8). Statistical analyses were performed with the
represent the SEM of samples within a group.naive B-cell reduction in the gut was TLR7-dependent.
IMQ-DTLR7 mice showed mild dermatitis compared with
control mice (Figure 4A and B), but showed no evidence of
gut B-cell reduction (Figure 4C). Thus, naive B-cell reduction
after IMQ treatment was TLR7-dependent, although it is
possible that the severity of dermatitis might impact the
magnitude of naive B-cell reductions in the gut. It has been
reported that mice treated with a combination of TLR3 and
TLR7 agonists show ameliorated DSS colitis because of
reduced TNF-a production by CD11bþ macrophages.12 To
explore the effects of route of administration, we treated the
mice with IMQ or phosphate-buffered saline (PBS) via
intraperitoneal (IP) injection (IMQ IP mice and PBS IP mice,
respectively) (Figure 4D). We observed increased absolute
numbers of macrophages and T cells in IMQ IP mice, as
previously reported (Figure 4E–G). However, B cells were
not decreased in IMQ IP mice (Figure 4H and I). We then
administered 2% (wt/vol) DSS to IMQ IP and PBS IP mice
(IMQ IP–DSS mice and PBS IP–DSS mice, respectively)
(Figure 4J). IMQ IP–DSS mice did not ameliorate colitis
compared with PBS IP–DSS mice (Figure 4K–N). Thus,
development of dermatitis was indispensable to recapitulate
the phenotype of exacerbated DSS-induced colitis after IMQ
treatment.
IMQ Dermatitis Altered Gut Microbial
Composition
It is well known that microbes and the immune system
interact with one another. For instance, some Clostridium
species induce Treg differentiation via short-chain fatty
acids, and secretory IgA coats fecal Escherichia coli in pa-
tients with Crohn’s disease.18 It was reported previously
that the microbiome composition in IBD patients was
similar to that of psoriasis patients.10,11 We hypothesized
that the microbiome composition of IMQ mice might differ
from control mice, and so we subjected fecal samples fromincrease intestinal permeability but altered immune cell
bility of mice induced psoriasis-like dermatitis (on day 17 of
lodaltons (right) FITC-dextran. Plasma FITC-dextran concen-
d 4 hours from oral administration of FITC-dextran (n ¼ 4, in
ed intravenously as a positive control. (B) Quantitative PCR
ical IMQ treatment (on day 17) analyzed by real-time PCR. (C)
ial cells after topical IMQ treatment (on day 17). Western blot
orescence staining was performed in control and IMQ mice.
n) stained with 40,6-diamidino-2-phenylindole (DAPI; blue) in
and the average positive area of each protein was compared
ents each mouse). (F) Quantitative PCR analysis for Reg IIIg in
analyzed by real-time PCR. (G) Representative plots of ﬂow
45þCD3-CD19- B220-NK1.1- colonic lamina propria after IMQ
nd absolute number (right) of macrophages in colonic lamina
þ (left) or CD80þ (right) macrophages. (I) Quantitative PCR
þs (n ¼ 3–4 in each group). (J) CD11bþ cells were sorted by
onuclear cells on day 17 of IMQ treatment (LP CD11bþs). LP
idoglycan (PGN) for 24 hours in vitro, and concentrations of
array. Unstimulated control was cultured with medium (Med).
ich are composed mainly of macrophages. Western blot (left)
2 independent experiments, in each group). (L) Percentage of
þCD11b-CD11cþ cells in colonic lamina propria (ILC3,
220þPDCA-1þ cells. Each symbol represents an individual
Student t test. *P < .05, **P < .01, ***P < .001. Error bars
2019 TLR7 Dermatitis Induces Severe DSS Colitis 141
142 Kiyohara et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 1both groups of mice to 16S ribosomal RNA (rRNA) meta-
genomic analysis. The number of operational taxonomic
units (OTUs), as well as a diversity measured using either
the Chao1 index or the phylogenetic diversity whole
tree metric, were comparable between the 2 groups
(Figure 5A). As we expected, a principal coordinate analysis
using the unweighted or weighted UniFrac distances
between microbial communities showed that the microbial
composition of IMQ mice was signiﬁcantly different from
control mice (Figure 5B). At the phylum level, Firmicutes
populations were slightly decreased and Bacteroidetes
populations were slightly increased in IMQ mice (Figure 5C).
At the family level, Lactobacillaceae populations were
reduced drastically in IMQ mice (Figure 5D and E), and both
Erysipelotrichaceae and Desulfovibrionaceae populations
were decreased to a lesser extent. At the genus level, we
observed a drastic reduction in Lactobacillus populations in
IMQ mice (Figure 5F–H), decreases in Desulfovibrio and
Allobaculum populations, and an increase in Dorea pop-
ulations. We concluded that psoriasis-like dermatitis altered
the gut microbial composition of IMQ-treated mice.Gut Microbiomes in IMQ Mice Are Essential to
Induce Severe DSS Colitis
Next, whether immunologic changes in IMQ mice were
caused directly by IMQ-induced dermatitis or by gut dys-
biosis, we applied either IMQ or vehicle alone to mice
along with a mixture of 4 antibiotics (Abx) (ampicillin,
neomycin, vancomycin, and metronidazole), targeting both
gram-positive and gram-negative bacteria (Abx-IMQ mice
and Abx-cont mice, respectively) (Figure 6A). Interestingly,
the number of B cells in the colonic lamina propria, but not
the number of macrophages, was reduced in Abx-IMQ mice
compared with Abx-cont mice (Figure 6B–H). These results
indicated that topical application of IMQ directly decreased
B cells in the gut in a microbe-independent manner,
whereas the increased number of macrophages might
result from IMQ-induced dysbiosis. To further conﬁrm the
role of intestinal microbes in IMQ mice, we tested whether
antibiotic therapy rescued the aggravation of colitis in
IMQ-DSS mice. We administered either the 4-Abx mixtureFigure 3. (See previous page). The reduction of IgDD and
migration to skin or skin draining lymph nodes, or by sy
cytometry analysis for lymphocytes in CD45þ colonic lamina
(right) of (B) T cells and (C) B cells in CD45þ colonic lamina p
cytometry analysis for IFN-g and IL17A in CD3þCD4þ cells fro
node (MLN), stimulated with PMA, ionomycin, and IL23 for 4 ho
in CD3þCD4þ lymphocytes from each organ. (F and G) Intra
phocytes from each organ. (H) Absolute number of IgAþ B
(I) Percentage in CD45þ cells of IgAþB220- plasma cells. (J)
immunosorbent assay. (K) Percentage of IgA-coated bacteria
ysis for B cells in epidermis, dermis, skin dLNs, spleen, and
indicate the percentages of gated cells. The plots are gated o
epidermis, dermis, skin dLN, spleen, and MLN as shown in
(middle), and IgMþ B cells (bottom) in skin dLN and MLN. Each
analyses were performed with the Student t test. *P < .05, **P
within a group.mentioned earlier or distilled water 3 times a week by oral
gavage to IMQ mice and control mice, starting 1 week
before topical treatment. After topical treatment of IMQ or
vehicle, 2% (wt/vol) DSS in drinking water was adminis-
tered ad libitum to all mice. Abx or distilled water was
administered until the end of the experiment (Figure 6I).
We conﬁrmed that the degree of psoriasis-like dermatitis
was unaffected by treatment with Abx (Figure 6J). As ex-
pected, IMQ mice treated with Abx (Abx-IMQ-DSS) had
ameliorated colitis compared with IMQ mice without Abx
treatment (water-IMQ-DSS), including lesser body weight
loss, longer colon lengths, lower DAI scores, and less se-
vere histologic ﬁndings (Figure 6K–Q). The severity of
colitis was comparable in Abx-IMQ-DSS and Abx-cont-DSS
mice. Gut microbiomes have a crucial role to exacerbate
IMQ-DSS colitis.
It remained unclear whether immune cells or gut mi-
crobes in IMQ mice were the direct mediator of severe DSS
colitis. We hypothesized that dysbiosis in IMQ mice was
essential for accelerated colitis. To test this hypothesis, we
obtained fecal contents from control mice or IMQ mice and
performed fecal transfers to GF IQI mice (cont gnotobiote
[gnoto] mice and IMQ gnoto mice, respectively) in vinyl
isolators (Figure 7A). IMQ gnoto mice did not develop
spontaneous colitis (data not shown). We observed that
the ratio of IgDþ B cells in the gut of IMQ gnoto mice was
slightly reduced compared with cont gnoto mice, but we
observed no difference in macrophages and B-cell
numbers between these groups (Figure 7B–D). We then
fed DSS in drinking water to these mice 3 weeks after fecal
transplantation (Figure 7E). Mice transplanted with feces
from IMQ mice and treated with DSS (IMQ gnoto-DSS
mice) showed more severe clinical symptoms than mice
transplanted with control mouse feces (cont gnoto-DSS
mice), including lower body weight, shorter colon length,
loose stool consistency, and gross bleeding. This was re-
ﬂected in the higher partial DAI scores of these animals
(Figure 7F–I). Histologic analysis of colons of IMQ gnoto-
DSS mice showed more severe destruction of epithelial
integrity, loss of crypts, submucosal edema, and higher
intestinal inﬂammation with immune cell inﬁltrates; this
was reﬂected by higher histologic scores in these animalsIgMD B cells of colon in IMQ mice was not caused by
stemic B-cell depletion. (A) Representative plots of ﬂow
propria. (B and C) Percentage (left) and absolute number
ropria as shown in panel A. (D) Representative plots of ﬂow
m colonic lamina propria, skin dLN. and mesenteric lymph
urs. (E) Percentage of IFN-gþ (top) and IL17Aþ (bottom) cells
cellular staining and the ratio of Foxp3 in CD3þCD4þ lym-
cells (left), IgDþ B cells (middle), and IgMþ B cells (right).
Concentration of IgA in feces measured by enzyme-linked
in feces. (L) Representative plots of ﬂow cytometry anal-
MLN after topical IMQ treatment. The numbers within plots
n CD45þ cells. (M) Percentages of B cells in CD45þ cells in
panel L. (N) Absolute number of B cells (top), IgDþ B cells
symbol represents an individual mouse (n ¼ 4–8). Statistical
< .01, ***P < .001. Error bars represent the SEM of samples
Figure 4. Psoriasis-like dermatitis was required to induce immunologic changes in the gut and to exacerbate DSS
colitis. (A–C) Psoriasis-like dermatitis was induced by topical IMQ treatment in TLR7-/- mice (IMQ-DTLR7 mice) and WT mice
(WT-IMQ mice). As control, vehicle was applied to TLR7-/- mice (cont-DTLR7 mice) instead of IMQ, and the severity of
dermatitis and B cell change in colonic lamina propria were assessed. Skin appearance after induction of psoriasis-like
dermatitis by (A) IMQ, (B) Psoriasis Area and Severity Index (PASI) score, and (C) the percentage of B cells in colonic lam-
ina propria analyzed by ﬂow cytometry. (D–I) IMQ was injected IP to mice daily for a week and lymphocytes in colonic lamina
propria were analyzed. PBS was injected instead of IMQ as control. (D) Experimental protocol, (E) absolute number of lamina
propria mononuclear cells (LPMCs), (F) percentage in CD45þlineage- cells (left) and absolute number (right) of macrophages in
colonic lamina propria, (G) percentage in CD45þ cells (left) and absolute number (right) of T cells, and (H) B cells. (I) Per-
centages in the total B cells of IgAþ B cells, IgDþ B cells, and IgMþ B cells. (J) Experimental protocol. Mice injected IP with IMQ
or PBS were further administered 2% (wt/vol) DSS for 7 days to induce colitis, and the severity of colitis was assessed. (K)
Representative photograph of colon on day 7 of DSS colitis. (L) Body weight change during DSS administration. (M) Colon
length on day 7 of DSS colitis. (N) DAI score on day 7 of DSS colitis. Each symbol represents an individual mouse (n ¼ 3–5).
Statistical analyses were performed with the Student t test. *P < .05, **P < .01, ***P < .005. Error bars represent the SEM of
samples within a group. Lineage, CD3, CD19, B220, and NK1.1.
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sults indicate that the gut microbiomes of IMQ mice had
the potential to accelerate gut inﬂammation in the DSScolitis model. Based on these results, in concert with our
previous data, we concluded that dysbiosis in IMQ mice
was essential to accelerate DSS colitis.
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nor Fecal Transplantation Ameliorated Colitis in
IMQ-DSS Mice
We previously showed that dysbiosis in IMQ mice
caused more severe DSS-induced colitis. We next considered
whether microbiome alterations might be therapeutic for
IMQ mice. We transplanted the fecal contents of WT mice
to IMQ mice and fed them 2% DSS in their drinking water
(IMQ[wild-type (WT) fecal microbe transplantation (FMT)]-DSS mice)
(Figure 7L). IMQ(WT FMT)-DSS mice and IMQ-DSS mice
developed comparably severe colitis (Figure 7M–O). We
further analyzed the effects of speciﬁc bacterial strains on
IMQ-DSS mice. Because we had observed large reductions of
Lactobacillus populations in IMQ mice, we focused on
Lactobacillus species. Three major species of Lactobacillus
were detected in the feces of control mice. Lactobacillus
johnsonii and Lactobacillus reuteri made up approximately
55% and 40% of all Lactobacillus species in control mice,
respectively (Figure 5G). We conﬁrmed that those 2 species
were greatly reduced in the feces of IMQ mice (Figure 5H).
Several Lactobacillus species, including L johnsonii and L
reuteri, have been reported to have protective roles in in-
testinal inﬂammation.19–26 We inoculated either a cocktail of
L johnsonii and L reuteri or water to IMQ mice during DSS
treatment (IMQ[Lacto]-DSS mice or IMQ[water]-DSS mice,
respectively) (Figure 7P). IMQ(Lacto)-DSS mice did not show
ameliorated colitis compared with IMQ(water)-DSS mice
(Figure 7Q–S). Thus, although antibiotic therapy could rescue
IMQ-DSS colitis (Figure 6I–Q) and intestinal dysbiosis medi-
ated the exacerbation of DSS-induced colitis, neither fecal
transplantation nor treatment with cocktails of L johnsonii
and L reuteri ameliorated DSS colitis in IMQ mice.
Both Hematopoietic and Nonhematopoietic
TLR7-Positive Cells Enhance IMQ-DSS Colitis
We further analyzed whether hematopoietic or non-
hematopoietic cells were essential for IMQ-DSS colitis. After
irradiation to WT mice, we injected bone marrow cells ob-
tained from WT or TLR7-/- mice (WTbone marrow[BM]/
DTLR7BM). After 6 weeks of bone marrow transplantation,
we applied vehicle or IMQ (WTBM/DTLR7BM/WTBM-IMQ/
DTLR7BM-IMQ mice, respectively) (Figure 8A). We observed
DTLR7BM-IMQ mice induce dermatitis as well as WTBM-IMQ
mice (data not shown). Then, we inoculated 2% (wt/vol)
DSS to each groups of mice (WTBM-DSS/DTLR7BM-DSS/
WTBM-IMQ-DSS/DTLR7BM-IMQ-DSS mice, respectively).
Both IMQ dermatitis groups, WTBM-IMQ-DSS and DTLR7BM-
IMQ-DSS mice exacerbated colitis compared with WTBM-DSSFigure 5. (See previous page). IMQ-induced psoriasis-like
metagenomic analysis for fecal samples derived from mice afte
collected on day 17 of IMQ or vehicle treatment, as shown in Fig
based on unweighted UniFrac distances (left) and weighted Un
PC2) explained 45.1% and 89.9% in the principal coordinate an
respectively. (C) Phylum and (D) family level bacterial composit
dance of each (E) family and (F) genera. (G) Proportion of each La
3 dominant Lactobacillus species in control and IMQ mice.
Mann–Whitney U test, or (B) the Permanova test. *P < .05. Erromice or DTLR7BM-DSS mice, respectively, in body weight
loss, colon length, and DAI (Figure 8B–F). We also conﬁrmed
that DTLR7BM-IMQ-DSS mice had an increased histologic
score compared with DTLR7BM-DSS mice (Figure 8G and H).
These data showed that nonhematopoietic resident cells
that expressed TLR7 were responsible for the IMQ
dermatitis-DSS colitis model. Because DTLR7BM-DSS mice
ameliorated colitis compared with WTBM-DSS mice, TLR7-
positive hematopoietic cells also were involved in the
IMQ-colitis model.
Discussion
IBD and psoriasis are different diseases, involving
chronic inﬂammatory conditions in the gut and skin,
respectively. These conditions share several similarities,
both involving commensal microbial communities and
potential immune mechanisms. However, little is known
regarding potential mechanisms of interaction between
dermatitis and colitis. In this study, we ﬁrst showed that
psoriasis-like dermatitis triggered by a TLR7 agonist (IMQ)
exacerbated DSS-induced colitis. Second, we found that IMQ
dermatitis resulted in reduced numbers of IgDþ and IgMþ
B-cell numbers and increased numbers of nonfunctional
macrophages in the gut. Third, we showed that IMQ
dermatitis caused dysbiosis, which mediated accelerated
DSS colitis. The results of our study support the existence of
a skin–gut axis: skin inﬂammation fosters proinﬂammatory
conditions in the gut, resulting in dysbiosis and B-cell
reductions. Our study’s ﬁrst major result was the observa-
tion that IMQ-induced psoriasis-like dermatitis affected gut
immune cell composition. IMQ mice had dramatically
reduced IgDþ and IgMþ B cells and increased numbers of
macrophages that were impaired in their ability to produce
cytokines. The increase in macrophage number was abro-
gated in antibiotic-treated mice, suggesting that intestinal
microbes in IMQ mice were involved in increasing macro-
phage frequency. We then showed that IMQ dermatitis
decreased IgDþ and IgMþ B cells in a microbe-independent
manner. Interestingly, decreased numbers of IgDþ and IgMþ
B cells were not observed when IMQ was administered IP.
This suggests that IMQ dermatitis, but not IMQ itself, was
essential to reduce B cells in the gut. Other groups also have
reported that IgM-positive B cells were indispensable to
protect against DSS colitis in MyD88 knockout (KO) mice.27
B-cell intrinsic MyD88 signaling had a key role in the
resistance to DSS via the production of IgM. These data
support our ﬁndings that a massive reduction of IgMþ
B cells in IMQ mice induced severe DSS colitis. Furtherdermatitis alters gut microbial compositions. 16S rRNA
r IMQ or vehicle treatment (n ¼ 4 in each group). Feces were
ure 1A. (A) Number of OTUs. (B) Principal coordinate analysis
iFrac distances (right). The 2 principal components (PC1 and
alysis based on unweighted and weighted UniFrac distances,
ions of IMQ or vehicle-treated mice. (E and F) Relative abun-
ctobacillus species in control mice. (H) Relative abundance of
Statistical analyses were performed with (A, E, and F) the
r bars represent the SEM of samples within a group.
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reduction of IgDþ and IgMþ B cells in the gut. There are 2
obvious possibilities. One possibility involves IMQ triggering
systemic inﬂammation through the lymphatic vessels orblood stream. Body weight is reduced transiently during the
ﬁrst few days after topical IMQ application. However, the
frequencies of macrophages and B cells in the spleen were
not altered in IMQ mice. We conﬁrmed that B cells did not
2019 TLR7 Dermatitis Induces Severe DSS Colitis 147accumulate in skin and skin draining lymph nodes after IMQ
treatment, suggesting that B cells in the gut of IMQ mice
might not move to other organs. It previously has been
reported that systemic administration of TLR3 and TLR7
agonists ameliorated colitis through enhanced production of
IFN-b by activated pDCs upon TLR7 signaling.12 In contrast
to the previous report, the number of pDCs in the gut of IMQ
mice was unaltered. This discrepancy might be related to
the route of administration of IMQ (topical vs systemic). It is
well known that there is a variety of TLR7-expressing cells,
including B cells, pDCs, and c-ﬁber neurons. We also
conﬁrmed that DTLR7BM-IMQ-DSS mice had severe colitis
compared with DTLR7BM-DSS mice. These data indicated
that TLR7-expressed nonhematopoietic cells played signiﬁ-
cant roles in IMQ-DSS colitis. However, DTLR7BM-DSS had
less severe colitis compared with WTBM -DSS mice. It also
suggested that TLR7-expressing hematopoietic cells also
involved the skin–gut axis. According to the previous
experiments, the other possibility is a potential neuro-
immune interaction involving skin-affected gut sites.
Recently, peripheral TRPV1þNav1.8
þ nociceptive sensory
neurons have been reported to interact with dermal den-
dritic cells, which are the principal source of IL23 in the
skin, and this interaction was found to be essential for the
development of psoriasis-like dermatitis in IMQ-induced
models.28 Nociceptors are associated not only with local
skin inﬂammation, but transfer neurodamage signals to the
brain as pain. It once was thought that cytokines produced
by immune cells might induce sensory nerve activation and
pain signaling; however, recent studies have shown that
pathogens and neurodamage could directly activate noci-
ceptors, and that TLRs were instrumental in bilateral
interactions between neurons and immune cells. For
instance, C ﬁbers in the dermis are known to express
TLR729 and TLR4. Nociceptors sense pathogens through
TLR4, TLR7, and TRPV1.29–31 Similar to dermal nerves,
enteric neurons express TLR2 or TLR4,32 and glial cells
express TLR7.33 Gut microbes alter the phenotypes of mac-
rophages surrounding enteric neurons, and these macro-
phages directly regulate the activity of enteric neurons.34,35
Further studies are needed to elucidate the preciseFigure 6. (See previous page). A gut microbiome in IMQ mic
administered a mixture of ampicillin, neomycin, vancomycin, and
the experiment. IMQ treatment was started 1 week after starting
IMQ treatment (on day 17) were analyzed by ﬂow cytometry. (B
CD11bþCD64þ cells in CD45þCD3-CD19- B220-NK1.1- cells f
cytometry analysis, the ratio and cell number of CD19þ cells in C
Percentage in the total B cells (left) and absolute number (right
CD45þ cells from colon lamina propria mononuclear cells. (I) M
vancomycin, and metronidazole) or distilled water by oral gavag
treatment was started 1 week after starting Abx or distilled water
all mice for 7 days after topical treatment of IMQ or vehicle. (J) Ps
or vehicle treatment. (K) Body weight changes during administr
colitis. (M) Representative photograph of colon on day 7 of DSS
on day 7 of DSS colitis. (P) Representative H&E staining of dista
Histologic score for colitis on day 7 of DSS colitis (water-cont-D
IMQ-DSS, n ¼ 7). Each symbol represents an individual mouse.
1-way analysis of variance followed by the Tukey multiple co
represent the SEM of samples within a group. Data are pooledmechanisms of skin–brain–gut neuroimmune interactions.
Again, our results did not deny the concomitance of TLR7-
positive immune cells in the IMQ-DSS model because
DTLR7BM-DSS mice had less severe colitis compared with
WTBM-DSS mice.
Our study’s second major result was the demonstration
that IMQ treatment of mice induced dysbiosis, especially
marked reductions of Lactobacillus species, which mediated
severe DSS colitis. We conﬁrmed that total amounts of IgA in
feces and gut were not altered by IMQ treatment. Both
intestinal permeability and antimicrobial peptide produc-
tion were unchanged in IMQ mice. Future studies will need
to establish novel models to investigate connections
between B-cell reduction or neural damage in the gut and
dysbiosis. L johnsonii is known to have a protective role in
the 2,4,6-trinitrobenzene sulfonic acid colitis model.19,20
However, administration of Lactobacillus species did not
improve the outcome of DSS-induced colitis in IMQ mice. It
is possible that Lactobacillus species were insufﬁcient to
ameliorate DSS colitis once gut B cells were reduced below a
certain threshold. Antibiotic therapy in IMQ mice amelio-
rated colitis because this prevented the induction of path-
ogenic microbiome conditions in the gut during DSS
administration. We also assessed whether psoriasis-like
dermatitis worsened under conditions of colitis. However,
we could not observe any differences in the dermatitis of
DSS-treated mice compared with water-treated mice (data
not shown). Dermatitis induced dysbiosis and exacerbated
colitis, but the opposite did not occur in our model.
Potential correlations between IBD and psoriasis have
been explored using clinical evidence, including the overlap
of patients with the 2 diseases, gut microbe similarities
among patients with these conditions, and the success of
anti–TNF-a or anti-IL12/23p40 antibody therapies in
human diseases. Further studies are needed to ﬁll the gaps
between human clinical disease and mouse experimental
models. To this end, we showed that IMQ-induced psoriasis-
like dermatitis reduced IgDþ and IgMþ B cells in the gut and
altered the composition of the gut microbiome. We also
showed that the dysbiosis in IMQ mice involved colitogenic
microbes that exacerbated DSS colitis. Further studies aree is essential to induce severe DSS colitis. (A) Mice were
metronidazole by oral gavage 3 times a week until the end of
Abx treatment. Colonic lamina propria mononuclear cells after
and C) Flow cytometry analysis, the ratio and cell number of
rom colon lamina propria mononuclear cells. (D and E) Flow
D45þ cells from colon lamina propria mononuclear cells. (F–H)
) of (F) IgAþ B cells, (G) IgDþ B cells, and (H) IgMþ B cells in
ice were administered Abx (a mixture of ampicillin, neomycin,
e 3 times a week until the end of the experiment. Topical IMQ
. A total of 2% (wt/vol) DSS subsequently was administered to
oriasis Area and Severity Index (PASI) score on day 16 of IMQ
ation of DSS. (L) Body weight percentages on day 7 of DSS
colitis. (N) Colon length on day 7 of DSS colitis. (O) DAI score
l colon section on day 7 of DSS colitis. Scale bar: 100 mm. (Q)
SS and water-IMQ-DSS, n ¼ 11; Abx-cont-DSS, n ¼ 9; Abx-
Statistical analyses were performed with the Student t test or
mparison test. *P < .05, **P < .01, ***P < .001. Error bars
from 2 independent experiments.
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2019 TLR7 Dermatitis Induces Severe DSS Colitis 149needed to investigate the precise mechanisms connecting
dermatitis, intestinal immune cells, and the gut microbiome.
Our ﬁndings shed novel light on the skin–gut interaction
and potentially may lead to the development of new ther-
apeutic targets for IBD patients with psoriasis.
Materials and Methods
Animals
C57BL/6J female mice and IQI/Jic (germ-free ICR) mice
were purchased from Japan CLEA (Tokyo, Japan). TLR7-/-
mice were purchased from Oriental Bio Service (Tokyo,
Japan). Mice, except for the GF mice, were maintained under
speciﬁc pathogen-free (SPF) conditions. GF mice were bred
and maintained in vinyl isolators. All experiments were
approved by the Institutional Review Board for Animal Ex-
periments at Keio University and were performed according
to the institutional guidelines and home ofﬁce regulations.
IMQ-Induced Psoriasis-Like Dermatitis
At 7–8 weeks of age, mice were shaved on the back skin
under anesthesia. For anesthesia, a mixture of medetomi-
dine (0.3 mg/kg, 002949, lot 705160; Domitor; Nippon
Zenyaku Kogyo, Tokyo, Japan), midazoram (4.0 mg/kg,
27803229, lot FW3745; Sandoz, Holzkirchen, Germany),
and butorphanol (5.0 mg/kg, 005526, lot VETLF5; Vetor-
phale; Meiji Seika Pharma, Tokyo, Japan) was injected IP.
After shaving, commercially available 5% IMQ cream
(02507936, lot GSJ115A, Beselna Cream; Mochida Pharma-
ceutical) was applied topically (62.5 mg) on the backs of the
mice for 6 consecutive days, followed by 3 days for rest.
After 1 cycle for 9 days, mice were again treated for another
cycle (12 days of application of IMQ in total). Vehicle cream
(286202303, lot 8H38; Vaseline; KENEI Pharmaceutical,
Tokyo, Japan) was applied topically on the shaved back of
mice from the control group according to the same schedule
as the IMQ group. To assess the severity of psoriasis-like
dermatitis, the clinical Psoriasis Area and Severity Index
score was calculated. Erythema, scaling, and thickeningFigure 7. (See previous page). Fecal microbiome transplanta
transplanted with a fecal microbiome derived from control mice (
weeks after transplantation, immune cells were analyzed by ﬂow
CD11bþCD64þ cells in CD45þCD3-CD19-B220- NK1.1- cells fr
number (right) of B cells in CD45þ colonic lamina propria. (D) Per
the total B cells from colonic lamina propria (n ¼ 6–7 in each
gnoto mice (shown in panel A) were further induced with acute
days, the severity of colitis was assessed. (F) Representative ph
day 7 of DSS colitis. (H) Colon length on day 7 of DSS colitis. (I) P
calculated as the sum of scores for perianal bleeding (0–4) and d
loss component). (J) Representative H&E staining of distal co
Histologic score of colitis on day 7 of DSS (n ¼ 3–5 in each grou
subsequently were induced with colitis by 2% (wt/vol) DSS f
administered daily by oral gavage, from the day before starting
during administration of DSS and (N) the percentage of the initial
DAI score on day 7 of DSS colitis (n ¼ 6 in each group). (P) E
subsequently induced with colitis by 2% (wt/vol) DSS for 7 days
istered daily by oral gavage, from the day before starting DSS t
administration of DSS and (R) the percentage of the initial value
score on day 7 of DSS colitis (n ¼ 8 in each group). Each sym
performed with the Student t test. *P < .05, **P < .01, ***P < .0were scored independently on a scale from 0 to 4: 0, none;
1, slight; 2, moderate; 3, marked; and 4, very marked. Each
score was added and the total scores were provided.
DSS-Induced Colitis or Induction of Acute
Experimental Colitis
C57BL/6J mice and IQI mice were administered 2%
(wt/vol) and 3% (wt/vol) DSS (molecular weight,
36,00050,000 daltons, 160110, lots M7191 and Q3526; MP
Biomedicals, Santa Ana, CA), respectively, dissolved in sterile
distilled water ad libitum for 7 days. SPF mice were weighed
every day to determine the percentage of body weight loss
from baseline. Body weight loss, stool consistency, and rectal
bleeding were evaluated and scored for DAI. No weight loss
was registered as 0, weight loss of 1% to 5% from baseline
was assigned 1 point, weight loss of 6% to 10% from base-
line was assigned 2 points, weight loss of 11% to 20% from
baseline was assigned 3 points, and weight loss of more than
20% from baseline was assigned 4 points. For stool consis-
tency, 0 points were assigned for well-formed pellets, 2
points for pasty and semiformed stools that did not adhere to
the anus, and 4 points for liquid stools that adhered to the
anus. For bleeding, 0 was assigned for no blood, 2 points for
positive bleeding, and 4 points for gross bleeding.
Histology
A distal colon section after DSS-induced colitis and a skin
section after induction of psoriasis-like dermatitis were
collected and ﬁxed with 10% formalin (068-03841, lot
TWE1483; Wako, Tokyo, Japan). The ﬁxed samples were
embedded in parafﬁn, and stained with H&E at Morpho-
technology Co, Ltd (Sapporo, Japan). To evaluate the
severity of DSS-induced colitis, histologic scores were
determined with the colon section as previously described.20
Brieﬂy, 3 independent parameters—extent, inﬂammation,
and crypt damage—were assessed and scored as follows:
extent: scored 0 to 3 (0, none; 1, mucosa; 2, submucosa; 3,
transmural); inﬂammation: scored 0 to 3 (0, none; 1, slight;tion of IMQ mice exacerbated DSS colitis. (A) GF mice were
cont gnoto mice) or IMQ-treated mice (IMQ gnoto mice). Three
cytometry. (B) Percentage (left) and absolute number (right) of
om colonic lamina propria. (C) Percentage (left) and absolute
centage of IgAþ (left), IgDþ (middle), and IgMþ (right) B cells in
group). (E) Experimental protocol. Cont gnoto mice and IMQ
colitis by 3% (wt/vol) DSS. After administration of DSS for 7
otograph of colon on day 7 of DSS colitis. (G) Body weight on
artial DAI score on day 7 of DSS colitis. Partial DAI score was
iarrhea (0–4) (part of the DAI score except for the body weight
lon section on day 7 of DSS colitis. Scale bar: 100 mm. (K)
p). (L) Experimental protocol. Mice treated with IMQ or vehicle
or 7 days. Feces derived from control mice, or saline, was
DSS to the end of the experiment. (M) Body weight changes
value (day 0 of DSS) of body weight on day 7 of DSS colitis. (O)
xperimental protocol. Mice treated with IMQ or vehicle were
. A mixture of L johnsonii and L reuteri, or saline, was admin-
o the end of the experiment. (Q) Body weight changes during
(day 0 of DSS) of body weight on day 7 of DSS colitis. (S) DAI
bol represents an individual mouse. Statistical analyses were
01. Error bars represent the SEM of samples within a group.
Figure 8. Both hematopoietic and nonhematopoietic TLR7-positive cells enhance IMQ-DSS colitis. (A) Experimental
protocol. (B) Body weight changes during administration of DSS. (C) Body weight on day 7 of DSS colitis. (D) DAI score on day
7 of DSS colitis. (E) Representative photograph of colon on day 7 of DSS colitis. (F) Colon length on day 7 of DSS colitis. (G)
Representative H&E staining of distal colon section on day 7 of DSS colitis. Scale bar: 100 mm. (H) Histologic score for colitis
on day 7 of DSS colitis. Each symbol represents an individual mouse (n ¼ 5–6). Statistical analyses were performed with 1-way
analysis of variance followed by the Tukey multiple comparison test. *P < .05, **P < .01, ***P < .001. Error bars represent the
SEM of samples within a group.
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none; 1, basal one-third lost; 2, basal two-thirds lost; 3, only
surface epithelium intact; 4, entire crypt and epithelium
lost) were multiplied by scores of spreads that were from 1
to 4 (1, 0%25%; 2, 26%50%; 3, 51%75%; 4, 76%
100%). Each multiplied score was summed and deﬁned as a
histologic score (040).Preparation of Colonic Lamina Propria
Mononuclear Cells and Colonic Epithelial Cells
A mouse was euthanized by cervical dislocation and the
colon was collected without mesentery. The colon was
opened longitudinally and washed with Ca2þ, Mg2þ-free
Hank’s balanced salt solution (HBSS) (17460-15, lot
2019 TLR7 Dermatitis Induces Severe DSS Colitis 151L8A4406; Nacalai Tesque, Tokyo, Japan) to remove fecal
content. After washing, the colon was further cut into small
pieces and incubated with HBSS containing 1 mmol/L
dithiothreitol (15508-013; lot H1095A0517; Invitrogen,
Carlsbad, CA) and 5 mmol/L EDTA (15575038; lot
1624957; Thermo Fisher Scientiﬁc, Waltham, MA) for 30
minutes at 37C to remove the epithelial layer. After
removal of the epithelial layer, the mucosal pieces were
washed with HBSS and dissolved in solution by incubation
with HBSS containing 1.5% fetal bovine serum (10270-106,
lot 42Q1074K; Thermo Fisher Scientiﬁc), 1.0 to 3.0 mg/mL
collagenase (032-22364, lot PTQ3925; Wako), and 0.1 mg/mL
DNase (DN25-1G, lot SLBV1446; Sigma-Aldrich, St. Louis,
MO) for 1 hour at 37C. The dissolved solution was centri-
fuged at 1700 rpm for 5 minutes, and the pellet was
resuspended in 40% Percoll (17-0891-01, lot 10262818; GE
Healthcare, Chicago, IL) and overlaid on 75% Percoll. Percoll
gradient separation was performed by centrifugation at 2000
rpm for 20 minutes at 20C. Lamina propria mononuclear
cells were collected at the interphase between 40% and 75%
Percoll layers. For colonic epithelial cells, the supernatant
containing the removed epithelial layer as described earlier
was collected and centrifuged at 1700 rpm for 5 minutes at
4C and the pellet was resuspended in 40% Percoll. Percoll
gradient separation was performed as well. Epithelial cells,
existing in the upper layer, were collected, washed, and
resuspended with appropriate buffer. Colonic lamina propria
CD11bþ cells (LP CD11bþs) were obtained from colonic
lamina propria mononuclear cells by positive selection with
anti-CD11b MACS beads (130-049-601, lot 5151216079;
Miltenyi Biotech, Cologne, Germany), according to the man-
ufacturer’s instructions.Preparation of Epidermal and Dermal Cell
Suspensions
Back skin was harvested from mice after shaving. The
skin tissue was ﬂoated with the epidermal side up in 5 mL
of trypsin-EDTA solution and 0.05% trypsin–0.53 mmol/L
EDTA  4 Na (32778-34, lot L7R3660; Nacalai Tesque) and
incubated at 37C for 30 minutes. The epidermis and dermis
were separated with forceps. The epidermal tissue was
loosened by suction with a 50-mL syringe repeatedly and
cells were passed through a cell strainer (352360, lot
147164; Corning, New York, NY) and collected. Dermis was
cut into small pieces using scissors, and then incubated in 4
mL of RPMI-1640 containing 0.03% (wt/vol) Liberase TL
grade (05401020001, lot 29195900; Roche) and 10 U/mL of
DNase I (10104159001, lot 12487400; Roche, Basel,
Switzerland) for 60 minutes at 37C, shaking with rotation at
200 rpm, and the lysate was passed through a cell strainer
and the ﬁltered dermal cells were collected.Preparation of Skin Draining Lymph Node and
Mesenteric Lymph Node Cell Suspensions
Skin draining lymph nodes, proper axillary lymph nodes,
and subiliac lymph nodes were harvested from mice after
death. Mesenteric lymph nodes also were harvested as well.Fat tissues around these lymph nodes were removed care-
fully and the lymph nodes were homogenized manually in
HBSS and the lysates were ﬁltered through a cell strainer,
and the passed cells were collected for analysis.
Preparation of Spleen Cell Suspensions
Spleen was harvested from mice after death and homoge-
nized manually in HBSS. The lysates were ﬁltered through a
cell strainer. The passed cells were hemolyzed with 0.84%
(vol/wt) ammonium chloride (02424-55, lot M8E1936;
Nacalai), washed with HBSS, and collected for analysis.
Isolation of Peritoneal Cells
Mice were euthanized with isoﬂurane (099-06571;
Wako) and injected with 5 mL of cold PBS IP. After injection,
the abdomen was gently massaged and the injected ﬂuid
was collected as much as possible.
Flow Cytometry
The surface antigens of isolated single-cell suspensions
were pre-incubated with an FcgR-blocking monoclonal
antibody (anti-mouse CD16/32, 2.4G2, 553142, lot
7248907; BD Biosciences, San Diego, CA) for 20 minutes
before staining cell surface antigens. After FcgR blocking,
ﬂuorescence-conjugated speciﬁc monoclonal antibodies to
surface molecules were incubated at 4C and protected from
light for 30 minutes. After staining surface molecules, the
cells were washed and resuspended with PBS containing
0.5% (wt/vol) bovine serum albumin (BSA) (01863-48, lot
M7G7120; Nacalai). For ﬂow cytometry analysis, the FACS
Canto II system (BD Biosciences), which is available for 8
colors, was used. Data were analyzed by FlowJo Vx software
(Tree Star). The monoclonal antibodies used for staining
included the following: FITC anti-IgA (10-3, 559354, lot
5089919), FITC anti-CD4 (RM4-5, 553047, lot 4247833),
phycoerythrin (PE) anti-CD64 (X54-5/7.1.1, 558455, lot
2125512), PE anti-CD19 (1D3, 553786, lot 37168), PerCP-
Cy5.5 7-amino-actinomycin D (7-AAD, 5168981E, lot
5006667-1), PerCP-Cy5.5 anti-CD4 (RM4-5, 56115, lot
7027622/602570), PE-Cy7 anti-CD3 (145-2C11, 552774,
lot 6251919), APC-Cy7 anti-CD3 (145-2C11, 557596, lot
5163789), APC-Cy7 anti-CD19 (1D3, 557655, lot 5168575),
APC-Cy7 anti-B220 (RA3-6B2, 552094, lot 7090802), APC
anti-CD138 (281-2, 142506, lot 8197973), and Brilliant Vi-
olet 510 anti-CD45 (30-F11, 563891, lot 7293934) were
purchased from BD Biosciences. FITC anti-CD11b (M1/70,
11-0112-82, lot 4283564), FITC anti–IFN-g (XMG1.2, 11-
7311-82, lot 4332573), PE anti-IL17A (eBio17B7, 12-7177-81,
lot 4306419), and APC anti-Foxp3 (FJK-16s, 17-5773-80, lot
E07302-1636) were purchased from eBioscience. PE anti-IgM
(RMM-1, 406508, lot B106128), PE-Cy7 anti-B220 (RA3-
6B2, 103222, lot B139371), PE-Cy7 anti-CD80 (16-10A1,
104734, lot B181277), APC anti-CD206 (C068C2, 141707,
lot B218213), APC-Cy7 anti-NK1.1 (PK136, 108724, lot
B225146), Brilliant Violet 421 anti-IgD (11-26c.2a, 405725, lot
B244155), and Brilliant Violet 421 anti-CD3 (145-2C11,
100341, lot B220025) were purchased from BioLegend
(San Diego, CA).
Table 1.Quantitative Real-Time PCR Primer Sequences
Primer list 5’-3’
Rpl32 forward: ACAATGTCAAGGAGCTGGAG
Rpl32 reverse: TTGGGATTGGTGACTCTGATG
IL6 forward: ACCAGAGGAAATTTTCAATAGGC
IL6 reverse: TGATGCACTTGCAGAAAACA
IL10 forward: CCCATTCCTCGTCACGATCTC
IL10 reverse: TCAGACTGGTTTGGGATAGGTTT
IL12b forward: TGGTTTGCCATCGTTTTGCTG
IL12b reverse: ACAGGTGAGGTTCACTGTTTCT
Tnf-a forward: AGGGTCTGGGCCATAGAACT
Tnf-a reverse: CCACCACGCTCTTCTGTCTAC
Arg1 forward: CTCCAAGCCAAAGTCCTTAGAG
Arg1 reverse: AGGAGCTGTCATTAGGGACATC
Nos2 forward: GTTCTCAGCCCAACAATACAAGA
Nos2 reverse: GTGGACGGGTCGATGTCAC
ZO-1 forward: TGTCAGGCATTGGCTAGAGGTTC
ZO-1 reverse: GGCCAAGGCCATAATAAACTTTGAG
Occludin forward: GAGTTAACGTCGTGGACCGGTATC
Occludin reverse: CCCTGAAATACAAAGGCAGGAATG
RegⅢg forward: TTCCTGTCCTCCATGATCAAAA
RegⅢg reverse: CATCCACCTCTGTTGGGTTCA
Sequences of each primers used in the experiments are
shown.
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For intracellular cytokine staining, cells were incubated
for 4 hours in a humidiﬁed incubator with 5% CO2, in
RPMI-1640 medium containing 10% fetal bovine serum and
1% penicillin/streptomycin (15140-122, lot 1622132;
Thermo Fisher Scientiﬁc) with 50 ng/mL phorbol 12-
myristate-13-acetate (PMA) (P1585-1MG, lot SLBN5870V;
Sigma-Aldrich), 500 ng/mL ionomycin (10634-1MG, lot
127M4002V; Sigma-Aldrich), 50 ng/mL recombinant mouse
IL23 (14-8231-63, lot 4299410; eBioscience), and GolgiStop
(51-2092KZ, lot 6308707; BD Bioscience). After incubation,
FcgR blocking and surface antigen staining were performed
as described earlier. After that, dead cells were stained with
Fixable Viability Dye eFluor 780 (65-0865-14, lot 4333604;
eBioscience) for 30 minutes at 4C and protected from light.
The cells were washed and incubated with ﬁxation/per-
meabilization solution (00-5123-43, lot 1954346 and 00-
5223-56, lot 4333317; Invitrogen) overnight at 4C pro-
tected from light. Then intracellular cytokine was stained by
ﬂuorescence-conjugated monoclonal antibodies incubated
for 30 minutes at 4C and protected from light. The incu-
bated cells were washed and analyzed by ﬂow cytometry.
For staining of Foxp3-positive cells, the same procedure but
without stimulation with PMA, ionomycin, and IL23, was
performed.
Quantitative Real-Time Polymerase Chain
Reaction
Total RNA was extracted from single-cell suspensions by
the RNeasy Mini Kit (74106, lot 157045393; Qiagen, Venlo,
Netherlands) or the RNeasy Micro Kit (74004, lot
154052961; Qiagen) according to the manufacturer’s in-
structions. The complementary DNA was synthesized from
the extracted RNA via reverse-transcription using the iScript
complementary DNA Synthesis Kit (170-8891, lot
64086966; Bio-Rad, Hercules, CA) according to the manu-
facturer’s instructions. The obtained complementary DNA
was ampliﬁed by quantitative real-time polymerase chain
reaction (PCR) using primer sets (Table 1) and the SYBR
Green FAST qPCR Master Mix kit (KK4602, lot 004569-4-1;
Kapa Biosystems, Wilmington, MA), and gene expression
was quantiﬁed by comparative cycle threshold method.
Rpl32 was used as the internal control and relative gene
expression was determined compared with the expression
of internal control. For PCR reactions, samples were heated
at 95C for 3 minutes at ﬁrst, and repeated for 40 cycles of
the following 2 steps: 95C for 3 seconds and 60C for 20
seconds. The quantitative real-time PCR was performed by
the Step OnePlus real-time PCR system (Thermo Fisher
Scientiﬁc).
Cytokine Assay of Colonic Lamina Propria
CD11bþ Cells
LP CD11bþs were seeded on 96-well tissue culture
plates (5  105 cells/mL, 1  105/well) in RPMI-1640
medium containing 10% fetal bovine serum and 1% peni-
cillin/streptomycin (15140-122, lot 1622132; Thermo
Fisher Scientiﬁc), and stimulated with lipopolysaccharide(100 ng/mL) (L3012, lot 123M4094V; Sigma) or peptido-
glycan (10 mg/mL) (tlrl-pgnsa, lot PSA-36-01; Invitrogen)
for 24 hours at 37C in a humidiﬁed incubator with 5% CO2.
After incubation, the culture supernatants were collected
and stored at 80C until analysis. For measurement of
secreted cytokines in the culture supernatants, a cytometric
bead array Mouse Inﬂammation Kit (552364, 5261593; BD
Biosciences) was used and analyzed with a FACS Canto II
ﬂow cytometer (BD Biosciences).
Western Blot Analysis
Proteins were extracted using the M-PER Mammalian
Protein Extraction Reagent (78501, lot PL209289; Thermo
Fisher Scientiﬁc). The protein was denatured with
2-mercaptoethanol (1610710, lot 1071172; Bio-Rad) and
sodium dodecyl sulfate by boiling at 99C for 5 minutes,
and polyacrylamide gel electrophoresis was performed
with Mini-Protean TGX Gels (456-1096, lot 64121225; Bio-
Rad) and Tris/glycine/sodium dodecyl sulfate buffer
(1610772, lot 64087453; Bio-Rad) (sodium dodecyl
sulfate–polyacrylamide gel electrophoresis). After sodium
dodecyl sulfate–polyacrylamide gel electrophoresis, blotting
to polyvinylidene diﬂuoride membrane was performed at
60 V for 2 hours in Tris/glycine buffer (1610771, lot
64082418; Bio-Rad). After blotting, polyvinylidene diﬂuor-
ide membrane was rinsed and blocking was performed with
4% (vol/wt) skim milk (190-12865, lot LKR1611; Wako) for
1 hour at room temperature. Antibodies against b-actin
(4967S, lot 6; Cell Signaling Technology, Tokyo, Japan),
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San Diego, CA), and occludin (ab216327, lot GR3193464-11;
Abcam, Cambridge, UK) were used. Signal detection was
performed using Clarity Western ECL Substrate (1705061,
lot 102030523; Bio-Rad) and ImageQuant LAS 4000
(GE Healthcare). Densitometric analysis was performed
using ImageQuant TL (GE Healthcare).
16S rRNA Metagenomic Analysis
The extraction of bacterial DNA was obtained from the
samples of fecal content. The hypervariable V3–V4 region of
the 16S gene was ampliﬁed using Ex Taq Hot Start (RR006A,
lot AI20308A; Takara, Tokyo, Japan) and subsequently pu-
riﬁed using AMPure XP (A63881, lot 15023200; Beckman
Coulter, Atlanta, GA). Mixed samples were prepared by
pooling approximately equal amounts of each ampliﬁed
DNA and sequenced using the Miseq Reagent Kit V3 (600
cycle, 15043895, lot 10046122; Illumina, San Diego, CA) and
the Miseq sequencer (Illumina), according to the manufac-
turer’s instructions. Sequences were analyzed using the
QIIME software package version 1.9.1.36,37 Paired-end se-
quences were joined using a fastq-join tool in the ea-utils
software package.38 High-quality sequences per sample
(15,000) were chosen randomly from the quality ﬁlter-
passed sequences. After trimming off both primer se-
quences using cutadapt39 following chimera detection by
USEARCH40 de novo method, the sequences were assigned
to OTUs using the UCLUST algorithm41 with a sequence
identity threshold of 96%. Taxonomic assignments of each
OTU were made by similarity searching against the publicly
available 16S (RDP version 10.27 and CORE update
September 2, 2012) and the NCBI genome database using
the GLSEARCH program.
Antibiotic Treatment
To eliminate as much bacteria in the gut of SPF mice as
possible, 4 antibiotics—ampicillin (6.7 mg/mL, A9518-25G,
lot BCBR6229V; Sigma-Aldrich), neomycin (6.7 mg/mL,
N1876-25G, lot SLBN9098V; Sigma-Aldrich), vancomycin
(3.35 mg/mL, 226-01306, lot LKF6780; Wako), and
metronidazole (6.7 mg/mL, M3761-25G, lot MKBZ3056V;
Sigma-Aldrich)—were mixed and dissolved in sterile
distilled water in the ﬁnal concentrations described earlier
to target gram-positive and gram-negative bacteria broadly,
and were administered to mice (500 mL per mouse) by oral
gavage 3 times a week.31 The same amount of sterile
distilled water was given to mice in the control group on the
same schedule. In the experiments using antibiotics, they
were given to the mice until death.
Fecal Microbiome Transplantation
Feces were derived from IMQ-treated and untreated
C57BL/6J mice and stored at 80C until use. The feces
were dissolved in 1.5 mL PBS homogenized, and then
ﬁltered through a 100-mm nylon mesh strainer (352360, lot
147164; Corning). The ﬁltered contents were resuspended
with PBS in a total volume of 2 mL, of which 150 mL per
mouse was administered to GF mice in the vinyl isolator, or5 mL, of which 300 mL per mouse was administered to SPF
mice by oral gavage.
Oral Administration of Lactobacillus Species
A single strain of L johnsonii was isolated by cultivation
with fecal samples derived from C57BL/6J wild-type SPF
mice. Feces were cultured on MRS selective agar (288210,
lot 5272510; BD Biosciences) at 37C for 48 hours anaer-
obically. The single colonies were collected and screened by
PCR with the speciﬁc primer for L johnsonii (5’-CACTA
GACGCATGTCTAGAG-3’ and 5’-AGTCTCTCAACTCGGCTATG-
3’),32 and then identiﬁed by full-length 16S rRNA gene
sequencing (Techno Suruga Lab, Shizuoka, Japan). A single
strain of L reuteri was purchased from American Type
Culture Collection (ATCC23272). The isolated single strain
of L johnsonii and a single strain of L reuteri were cultured
on MRS selective broth (288130, lot 4307971; BD Bio-
sciences) for 24 hours anaerobically and centrifuged at
1700 rpm for 5 minutes. The deposit was dissolved in
sterile saline and then administered to SPF mice once a day
by oral gavage.
Bone Marrow Transplantation
Bone marrow was isolated from WT and TLR7-/- mice.
Bone marrow was obtained by ﬂushing the femurs and tibiae
of donor mice with RPMI-1640 (30264-85, lot L8H5874;
Nacalai Tesque). Recipient WT mice were lethally irradiated
with 11 Gy whole-body g irradiation (MBR-1520R-3; Hitachi
Co Ltd, Hitachi, Japan). After irradiation, the recipient mice
then were injected intravenously with 5  106 bone marrow
cells via tail vein. Mice then were housed for 6 weeks to allow
full engraftment of the bone marrow.
Immunoﬂuorescence
Parafﬁn-embedded distal colon sections from mice after
induction of psoriasis-like dermatitis were used for analysis
by immunoﬂuorescence. Antigen retrieval was performed in
boiled citric acid solution followed by blocking procedure.
The sections were blocked with Block Ace (UKB80, lot
STK102796; DS Pharma Biomedical Co, Ltd, Tokyo, Japan)
for 60 minutes at room temperature. After blocking, the
sections were incubated with primary antibodies overnight
at 4C. The primary antibodies were diluted with Dako
Antibody Diluent (S3022, lot 10125945; Dako) at the
following dilution rates. Mouse anti-occludin antibody (33-
1500, lot SB231108; Abcam) and rabbit anti–ZO-1 poly-
clonal antibody (61-7300, lot SH252320; Invitrogen) were
both at 1:100, and rabbit anti–claudin 2 antibody (ab53032,
lot GR314368-12; Abcam) was at 1:200. After rinsing,
the sections were incubated with ﬂuorescence-conjugated
secondary antibodies as follows, for 2 hours at room
temperature while protected from light. Alexa Fluor
647–conjugated donkey anti-mouse IgG (ab150107, lot
GR292574-3; Abcam), Alexa Fluor 488–conjugated donkey
anti-rabbit IgG (ab150073, lot GR3191541; Abcam) both
were diluted at 1:250. After rinsing, the sections were
mounted with mounting medium and visualized by using an
LSM 710 confocal laser scanning microscope (Carl Zeiss,
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image-processing and analysis software package for digital
microscopy. Quantitative analysis for immunoﬂuorescence
images were performed by using ImageJ software (National
Institutes of Health, Bethesda, MD).
Intraperitoneal Injection of IMQ
For systemic administration of IMQ, imiquimod (R837)
(tlrl-imq, lot IMQ-36-02A; Invivogen) was dissolved with
endotoxin-free water at 1 mg/mL and injected IP (10 mg/
kg) daily for a week.
Enzyme-Linked Immunosorbent Assay for
Measurement of Fecal IgA
Feces derived from mice were dissolved in PBS con-
taining 1% (wt/vol) BSA and 0.05% (vol/vol) Tween20 at
a concentration of 100 mg/mL, and homogenized. To
remove debris, these homogenized samples were centri-
fuged stepwise with increasing force (400g for 5 min,
8000g for 10 min, and 19,000g for 10 min). The su-
pernatant was collected and the IgA concentration was
measured by IgA Mouse Enzyme-Linked Immunosorbent
Assay kit (88-50450-88, lot 146856016; Thermo Fisher
Scientiﬁc) according to the manufacturer’s instructions.
The absorbance was measured at a wavelength of 450 nm
and the reference wave length was 550 nm using Inﬁnite
F200 PRO (Tecan, Männedorf, Switzerland).
Analysis for Fecal IgA-Coated Bacteria
Feces were collected and dissolved in PBS, homoge-
nized, and ﬁltered through a 40-mm nylon mesh strainer.
The ﬁltered contents were centrifuged at 9000g for
10 minutes at 4C and the supernatant was discharged.
The deposits were resuspended with 10 mL PBS and
centrifuged twice as well. The deposit then was resus-
pended with PBS in a total volume of 2 mL and then
centrifuged at 50g for 5 minutes at 4C, and the super-
natant was collected. The collected supernatant was ﬁrst
stained for bacteria with the Bacteria Counting Kit for ﬂow
cytometry (B7277, lot 1868123; Thermo Fisher Scientiﬁc)
according to the manufacturer’s instructions. Then the
samples were washed with PBS, and incubated with 1%
(wt/vol) BSA/PBS containing rat serum (R9759-5ML, lot
SLBR6771V; Sigma-Aldrich) for blocking on ice for 30
minutes. The incubated samples subsequently were
stained by PE anti-IgA (12-4204-83, lot E01650-1634;
eBioscience) or PE Rat-IgG1k isotype control (12-4301-
82, lot E01654-1633; eBioscience) for 30 minutes on ice
and protected from light. The samples were washed with
1% BSA/PBS and centrifuged twice and analyzed by ﬂow
cytometry.
Analysis for Intestinal Permeability With FITC-
Dextran
Intestinal permeability was assessed by administration
of FITC-dextran (average molecular weight, 4 kilodaltons
and 70 kilodaltons, respectively, FD4-250MG, lotBCBS4210V and FD70S-100MG, lot SLBT8689; Sigma-
Aldrich) with slight modiﬁcation. Brieﬂy, mice were kept
fasting for 6 hours before administration of FITC-dextran. A
total of 60 mg/kg FITC-dextran was given to mice by oral
gavage or IP injection, and the plasma concentration of
FITC-dextran was determined by ﬂuorescence intensity at
1, 2, and 4 hours after administration of FITC-dextran. The
ﬂuorescence intensity was measured by Inﬁnite F200 PRO
(Tecan).Statistical Analysis
The results are expressed as means ± SEM. Groups of
data were compared with 1-way analysis of variance with
the Tukey multiple comparison post hoc analysis or the
Student t test or Mann–Whitney U test, except for
the principal coordinate analysis for the gut microbiome.
The differences in the principal coordinate analysis were
analyzed with the Permanova test. The difference was
considered signiﬁcant when the P value was less than .05.References
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